Luhut Binsar Pandjaitan, Coordinating Minister for Maritime Affairs and Investments revealed that there is a company from China that is planned to work with local companies to produce vaccines in Indonesia.
The vaccine factory is planned to produce an mRNA vaccine in April 2022.
Economists claim that there will be opportunities and employment for the collaboration of the two countries. Not only that, the collaboration of vaccine factories between Indonesia and China can save logistics costs.
The potential for Covid-19 to become endemic makes collaboration in vaccine production considered important for the community.
Economists noted related to the flow of foreign investment through the collaboration of the two countries in producing vaccines.
The vaccine development technology that is brought in must have a technology transfer guarantee to the Indonesian side. The guarantee must have been transferred to Indonesia within two years.
In terms of research, experts in Indonesia have the opportunity to conduct international research. In other words, the government needs to ensure the involvement of Indonesian experts in planning, establishment, and production. This needs to be done so that the technology transfer process can be achieved.
The involvement of the private sector and domestic vaccine producers must also be considered. This is so that the multiplier effect of establishing a collaborative factory between Indonesia and China can have a big impact in strengthening the health sector, especially the availability of vaccines.